TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy
Luca Hegedüs, Özlem Okumus, Fabian Mairinger, Till Ploenes, Sebastian Reuter, Martin Schüler, Anja Welt, Silvia Vega-Rubín-de-Celis, Dirk Theegarten, Ágnes Bánkfalvi, Clemens Aigner, Balázs Hegedűs
Topics & Concepts
MedicineCancer researchCell cultureFlow cytometryViability assayAntibody-drug conjugateCellMesotheliomaAntibodyPathologyMonoclonal antibodyImmunologyBiologyGeneticsOccupational and environmental lung diseasesHER2/EGFR in Cancer ResearchPeptidase Inhibition and Analysis